This appraisal is only looking at locally advanced or metastatic breast cancer that has progressed after only 1 chemotherapy regimen. A positive recommendation on eribulin for treating locally advanced or metastatic breast cancer in adults who have had 2 or more chemotherapy regimens is given in a separate NICE technology appraisal (TA423) https://www.nice.org.uk/guidance/ta423